About This Trial
Antibody-drug conjugate targeting Trop2 with novel topoisomerase I inhibitor payload.
Primary Endpoints
- Progression-free survival
- Overall survival
Latest Update
February 2026
Met primary PFS endpoint with 6.9 month improvement vs chemotherapy. FDA filing imminent.